Mallika Lala

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 33 篇 · 总被引 1393 次 · h-index 15

代表论文

• First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ (2021 · Annals of Oncology · 被引 299)
• Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection (2016 · Antimicrobial Agents and Chemotherapy · 被引 185)
• A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation (2020 · European Journal of Cancer · 被引 164)
• Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review (2019 · Breast Cancer Research · 被引 149)
• Clarification on Precision Criteria to Derive Sample Size When Designing Pediatric Pharmacokinetic Studies (2011 · The Journal of Clinical Pharmacology · 被引 115)
• Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review (2018 · Oral Oncology · 被引 86)